Vaxcyte, Inc.: T. Rowe Price Investment Management, Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
T. Rowe Price Investment Management amended its Schedule 13G filing for Vaxcyte, Inc., updating its disclosed stake in the clinical-stage vaccine developer with the SEC under accession number 0001897612-26-000700. The filing reflects a change in the asset manager's reported position, though the headline did not specify the exact share count or percentage. The disclosure matters because institutional ownership shifts can signal changing conviction in Vaxcyte, which is developing pneumococcal conjugate vaccine candidates. Investors will watch for the amended filing's detailed holdings and any subsequent 13F or 13G updates for further clarity on T. Rowe Price's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
T. Rowe Price Investment Management, Inc., Vaxcyte, Inc.